Metabolism Branch
Head, Lymphoma Therapeutics Section
Senior Investigator

National Cancer Institute
9000 Rockville Pike
Building 10, Room 4N-115
Bethesda, MD 20892

Phone: 301-435-2415
Fax: 301-480-4087
wilsonw@mail.nih.gov

Dr. Wilson received his B.A. and M.S. in biology from Stanford University in 1975. In 1981, he received his Ph.D. in neurobiology and M.D. from Stanford, and he completed residency training in internal medicine at Stanford in 1984. From 1984 to 1987, he was a clinical associate in the Medicine Branch, NCI, where he completed a fellowship in medical oncology. Dr. Wilson was special assistant to the director, Division of Cancer Treatment, NCI, from 1988 to 1995. In 1995, he joined the former Medicine Branch as a senior oncologist.

Dr. Wilson's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with leukemia or lymphoma. Click on the trial(s) below for additional details, including a summary of eligibility criteria, study outline, and information on how to contact the study team directly.

A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies NCI-07-C-0006

Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas NCI-05-C-0252

Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics NCI-05-C-0170

Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas NCI-04-C-0173

Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas NCI-01-C-0030

Treatment and Natural History Study of Lymphomatoid Granulomatosis NCI-94-C-0074

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma NCI-93-C-0133 (Multi-center study)